International Edition
Latest News
Health

Lubdub ECG Patch Begins Clinical Trial at Perth Clinic

A wearable, gel-free ECG patch developed by Australian start-up Lubdub entered clinical trial this week at Midlands Medical Specialists in Perth. The patch continuously records heart rhythm for up to 14 days and produced signals 18 times cleaner…

A wearable, gel-free ECG patch developed by Australian start-up Lubdub entered clinical trial this week at Midlands Medical Specialists in Perth.

The patch continuously records heart rhythm for up to 14 days and produced signals 18 times cleaner than traditional Holter monitors in earlier testing with healthy volunteers, RMIT University and Lubdub said. Patients already prescribed a Holter monitor will wear the prototype simultaneously so clinicians can compare the datasets.

RMIT Professor and Lubdub co-founder Sharath Sriram said the flexible sensors make better skin contact than the wired electrodes used in standard Holter monitors. “By reducing the work needed to generate cardiac reports, the technology could allow the same workforce to monitor up to 85% more patients before other enabling tools like AI are implemented,” Sriram said.

The trial aims to gather evidence for regulatory approval. Lubdub plans to combine the ECG patch with non-invasive cardiac biomarker testing and wearable ultrasound imaging in a single software platform. RMIT licensed the intellectual property for the ECG and biomarker inventions to the company.

Lubdub secured an oversubscribed $6 million seed round that month, doubling its $3 million target, backed mainly by physicians and heart specialists. The Heart Foundation named the company one of its 10 most promising heart health projects for 2026.

Co-founder and director Nikhilesh Bappoo said the mission is personal. His father suffered a heart attack in Perth and received timely specialist care, but Bappoo said the outcome could have been very different in Mauritius, where he grew up.

“Had it happened there, the outcome could have been very different,” he said.

Cardiovascular disease causes a third of deaths globally and nearly a quarter in Australia. Sriram said most heart failure diagnoses and hospital admissions are unplanned emergencies, yet many patients report symptoms for years earlier. “Our innovation is about simpler and more effective screening, because prevention is better than cure,” he said.

About the author: Health Desk

Health Desk at Archynewsy.